Ranbaxy licenses Medy-Tox's Neuronox in India
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories has signed a licensing agreement with Medy-Tox, South Korea's largest botulinum–toxin biotech venture, for the latter's cosmetic product, Neuronox, in India.